96 related articles for article (PubMed ID: 29258411)
1. Calreticulin Affects Hematopoietic Stem/Progenitor Cell Fate by Impacting Erythroid and Megakaryocytic Differentiation.
Salati S; Prudente Z; Genovese E; Pennucci V; Rontauroli S; Bartalucci N; Mannarelli C; Ruberti S; Zini R; Rossi C; Bianchi E; Guglielmelli P; Tagliafico E; Vannucchi AM; Manfredini R
Stem Cells Dev; 2018 Feb; 27(4):225-236. PubMed ID: 29258411
[TBL] [Abstract][Full Text] [Related]
2. Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants.
Salati S; Genovese E; Carretta C; Zini R; Bartalucci N; Prudente Z; Pennucci V; Ruberti S; Rossi C; Rontauroli S; Enzo E; Calabresi L; Balliu M; Mannarelli C; Bianchi E; Guglielmelli P; Tagliafico E; Vannucchi AM; Manfredini R
Sci Rep; 2019 Jul; 9(1):10558. PubMed ID: 31332222
[TBL] [Abstract][Full Text] [Related]
3. Skewed megakaryopoiesis in human induced pluripotent stem cell-derived haematopoietic progenitor cells harbouring calreticulin mutations.
Takei H; Edahiro Y; Mano S; Masubuchi N; Mizukami Y; Imai M; Morishita S; Misawa K; Ochiai T; Tsuneda S; Endo H; Nakamura S; Eto K; Ohsaka A; Araki M; Komatsu N
Br J Haematol; 2018 Jun; 181(6):791-802. PubMed ID: 29741776
[TBL] [Abstract][Full Text] [Related]
4. The Expression of Myeloproliferative Neoplasm-Associated Calreticulin Variants Depends on the Functionality of ER-Associated Degradation.
Mansier O; Prouzet-Mauléon V; Jégou G; Barroso K; Raymundo DP; Chauveau A; Dumas PY; Lagarde V; Turcq B; Pasquet JM; Viallard JF; James C; Praloran V; Voutetakis K; Chatziioannou A; Mahon FX; Chevet E; Lippert E
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31810292
[TBL] [Abstract][Full Text] [Related]
5. Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis.
Daitoku S; Takenaka K; Yamauchi T; Yurino A; Jinnouchi F; Nunomura T; Eto T; Kamimura T; Higuchi M; Harada N; Saito N; Miyamoto T; Iwasaki H; Akashi K
Exp Hematol; 2016 Sep; 44(9):817-825.e3. PubMed ID: 27185380
[TBL] [Abstract][Full Text] [Related]
6. Impact of Calreticulin and Its Mutants on Endoplasmic Reticulum Function in Health and Disease.
Arshad N; Cresswell P
Prog Mol Subcell Biol; 2021; 59():163-180. PubMed ID: 34050866
[TBL] [Abstract][Full Text] [Related]
7. Calreticulin mutations affect its chaperone function and perturb the glycoproteome.
Schürch PM; Malinovska L; Hleihil M; Losa M; Hofstetter MC; Wildschut MHE; Lysenko V; Lakkaraju AKK; Maat CA; Benke D; Aguzzi A; Wollscheid B; Picotti P; Theocharides APA
Cell Rep; 2022 Nov; 41(8):111689. PubMed ID: 36417879
[TBL] [Abstract][Full Text] [Related]
8. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Imai M; Araki M; Komatsu N
Int J Hematol; 2017 Jun; 105(6):743-747. PubMed ID: 28470469
[TBL] [Abstract][Full Text] [Related]
9. Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms.
Martin S; Wright CM; Scott LM
Br J Haematol; 2017 Apr; 177(1):55-66. PubMed ID: 28168700
[TBL] [Abstract][Full Text] [Related]
10. Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms.
El-Khoury M; Cabagnols X; Mosca M; Vertenoeil G; Marzac C; Favale F; Bluteau O; Lorre F; Tisserand A; Rabadan Moraes G; Ugo V; Ianotto JC; Rey J; Solary E; Roy L; Rameau P; Debili N; Pasquier F; Casadevall N; Marty C; Constantinescu SN; Raslova H; Vainchenker W; Plo I
Oncogene; 2020 Jul; 39(31):5323-5337. PubMed ID: 32572159
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppression by Mutated Calreticulin Released from Malignant Cells.
Liu P; Zhao L; Loos F; Marty C; Xie W; Martins I; Lachkar S; Qu B; Waeckel-Énée E; Plo I; Vainchenker W; Perez F; Rodriguez D; López-Otin C; van Endert P; Zitvogel L; Kepp O; Kroemer G
Mol Cell; 2020 Feb; 77(4):748-760.e9. PubMed ID: 31785928
[TBL] [Abstract][Full Text] [Related]
12. [Development of myeloproliferative neoplasms by mutant calreticulin: underlying mechanisms].
Araki M
Rinsho Ketsueki; 2018; 59(8):1072-1077. PubMed ID: 30185708
[TBL] [Abstract][Full Text] [Related]
13. Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.
Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Camacho L; Fernández-Rodríguez MC; Pairet S; Besses C
Leuk Res; 2016 Sep; 48():11-5. PubMed ID: 27427771
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
[TBL] [Abstract][Full Text] [Related]
15. Calreticulin and cancer.
Fucikova J; Spisek R; Kroemer G; Galluzzi L
Cell Res; 2021 Jan; 31(1):5-16. PubMed ID: 32733014
[TBL] [Abstract][Full Text] [Related]
16. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
Elf S; Abdelfattah NS; Chen E; Perales-Patón J; Rosen EA; Ko A; Peisker F; Florescu N; Giannini S; Wolach O; Morgan EA; Tothova Z; Losman JA; Schneider RK; Al-Shahrour F; Mullally A
Cancer Discov; 2016 Apr; 6(4):368-81. PubMed ID: 26951227
[TBL] [Abstract][Full Text] [Related]
17. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
18. Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative Neoplasms.
Secardin L; Gomez Limia C; da Silva-Benedito S; Lordier L; El-Khoury M; Marty C; Ianotto JC; Raslova H; Constantinescu SN; Bonamino MH; Vainchenker W; Monte-Mor B; Di Stefano A; Plo I
Hemasphere; 2021 Jul; 5(7):e593. PubMed ID: 34131633
[TBL] [Abstract][Full Text] [Related]
19. Systems biology surveillance decrypts pathological transcriptome remodeling.
Faustino RS; Wyles SP; Groenendyk J; Michalak M; Terzic A; Perez-Terzic C
BMC Syst Biol; 2015 Jul; 9():36. PubMed ID: 26179794
[TBL] [Abstract][Full Text] [Related]
20. Screening for calreticulin mutations in a cohort of patients suspected of having a myeloproliferative neoplasm.
De Kock A; Booysen C
S Afr Med J; 2016 Dec; 106(12):1260-1262. PubMed ID: 27917774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]